Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy

Robert G. Masterton; A. Galloway; G. French; M. Street; J. Armstrong; E. Brown; J. Cleverley; P. Dilworth; Carole Fry; A. D. Gascoigne; Alan Knox; Dilip Nathwani; Robert Spencer; Mark Wilcox

doi:10.1093/jac/dkn162

Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy

Robert G. Masterton^*, A. Galloway, G. French, M. Street, J. Armstrong, E. Brown, J. Cleverley, P. Dilworth, Carole Fry, A. D. Gascoigne, Alan Knox, Dilip Nathwani, Robert Spencer, Mark Wilcox

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

259 Citations (Scopus)

Abstract

These evidence-based guidelines have been produced after a systematic literature review of a range of issues involving prevention, diagnosis and treatment of hospital-acquired pneumonia (HAP). Prevention is structured into sections addressing general issues, equipment, patient procedures and the environment, whereas in treatment, the structure addresses the use of antimicrobials in prevention and treatment, adjunctive therapies and the application of clinical protocols. The sections dealing with diagnosis are presented against the clinical, radiological and microbiological diagnosis of HAP. Recommendations are also made upon the role of invasive sampling and quantitative microbiology of respiratory secretions in directing antibiotic therapy in HAP/ventilator-associated pneumonia.

Original language	English
Pages (from-to)	5-34
Number of pages	30
Journal	Journal of Antimicrobial Chemotherapy
Volume	62
Issue number	1
DOIs	https://doi.org/10.1093/jac/dkn162
Publication status	Published - Jul 2008

Bibliographical note

Funding Information:
A. G. has received funds for speaking at a symposium organized on behalf of Wyeth Pharmaceuticals Ltd. R. S. has received personal remuneration for speaking at an educational meeting organized by Wyeth. R. G. M. has received speaker honoraria from AstraZeneca and Wyeth. D. N. presently is a member of a number of UK and European Pharmaceutical Advisory boards (tigecycline, Wyeth; ceftobiprole, Janssen-Cilag; daptomycin, Novartis; linezolid, Pfizer; and OPT-80, Optimer). He has received honoraria to speak at meetings organized by Pfizer, Wyeth and Novartis. M. W. has received honoraria for consultancy work, financial support to attend meetings and research funding from AstraZeneca, Bayer, Genzyme, Nabriva, Pfizer, Vicuron and Wyeth. A. D. G. and M. S. have received funds for speaking at symposia organized on behalf of Wyeth and E. B. has received fees for speaking at a symposium sponsored by Novartis and for being a member of advisory panels for Chiron, Novartis and Janssen-Cilag. He has also received sponsorship from Chiron to attend a conference. J. A., A. K., G. F., P. D., J. C. and C. F. have none to declare.

Funding Information:
We would like to acknowledge Corvus Communications Ltd and particularly Alison Crowe and Alistair Knight from within that company. Corvus Communications Ltd acted as the secretariat throughout this project and their support was from an unrestricted educational grant from Wyeth Pharmaceuticals Ltd, to whom we are also grateful for such funding.

Keywords

Antimicrobial treatment
Diagnosis
Evidence-based guidelines
Healthcare-associated pneumonia
Hospital-acquired pneumonia
Prevention

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkn162

Cite this

Masterton, R. G., Galloway, A., French, G., Street, M., Armstrong, J., Brown, E., Cleverley, J., Dilworth, P., Fry, C., Gascoigne, A. D., Knox, A., Nathwani, D., Spencer, R., & Wilcox, M. (2008). Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy. Journal of Antimicrobial Chemotherapy, 62(1), 5-34. https://doi.org/10.1093/jac/dkn162

@article{5516be9b19c64a06b7683626da2a0583,

title = "Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy",

abstract = "These evidence-based guidelines have been produced after a systematic literature review of a range of issues involving prevention, diagnosis and treatment of hospital-acquired pneumonia (HAP). Prevention is structured into sections addressing general issues, equipment, patient procedures and the environment, whereas in treatment, the structure addresses the use of antimicrobials in prevention and treatment, adjunctive therapies and the application of clinical protocols. The sections dealing with diagnosis are presented against the clinical, radiological and microbiological diagnosis of HAP. Recommendations are also made upon the role of invasive sampling and quantitative microbiology of respiratory secretions in directing antibiotic therapy in HAP/ventilator-associated pneumonia.",

keywords = "Antimicrobial treatment, Diagnosis, Evidence-based guidelines, Healthcare-associated pneumonia, Hospital-acquired pneumonia, Prevention",

author = "Masterton, {Robert G.} and A. Galloway and G. French and M. Street and J. Armstrong and E. Brown and J. Cleverley and P. Dilworth and Carole Fry and Gascoigne, {A. D.} and Alan Knox and Dilip Nathwani and Robert Spencer and Mark Wilcox",

note = "Funding Information: A. G. has received funds for speaking at a symposium organized on behalf of Wyeth Pharmaceuticals Ltd. R. S. has received personal remuneration for speaking at an educational meeting organized by Wyeth. R. G. M. has received speaker honoraria from AstraZeneca and Wyeth. D. N. presently is a member of a number of UK and European Pharmaceutical Advisory boards (tigecycline, Wyeth; ceftobiprole, Janssen-Cilag; daptomycin, Novartis; linezolid, Pfizer; and OPT-80, Optimer). He has received honoraria to speak at meetings organized by Pfizer, Wyeth and Novartis. M. W. has received honoraria for consultancy work, financial support to attend meetings and research funding from AstraZeneca, Bayer, Genzyme, Nabriva, Pfizer, Vicuron and Wyeth. A. D. G. and M. S. have received funds for speaking at symposia organized on behalf of Wyeth and E. B. has received fees for speaking at a symposium sponsored by Novartis and for being a member of advisory panels for Chiron, Novartis and Janssen-Cilag. He has also received sponsorship from Chiron to attend a conference. J. A., A. K., G. F., P. D., J. C. and C. F. have none to declare. Funding Information: We would like to acknowledge Corvus Communications Ltd and particularly Alison Crowe and Alistair Knight from within that company. Corvus Communications Ltd acted as the secretariat throughout this project and their support was from an unrestricted educational grant from Wyeth Pharmaceuticals Ltd, to whom we are also grateful for such funding.",

year = "2008",

month = jul,

doi = "10.1093/jac/dkn162",

language = "English",

volume = "62",

pages = "5--34",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "1",

}

Masterton, RG, Galloway, A, French, G, Street, M, Armstrong, J, Brown, E, Cleverley, J, Dilworth, P, Fry, C, Gascoigne, AD, Knox, A, Nathwani, D, Spencer, R & Wilcox, M 2008, 'Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy', Journal of Antimicrobial Chemotherapy, vol. 62, no. 1, pp. 5-34. https://doi.org/10.1093/jac/dkn162

Guidelines for the management of hospital-acquired pneumonia in the UK : Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy. / Masterton, Robert G.; Galloway, A.; French, G. et al.

In: Journal of Antimicrobial Chemotherapy, Vol. 62, No. 1, 07.2008, p. 5-34.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Guidelines for the management of hospital-acquired pneumonia in the UK

T2 - Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy

AU - Masterton, Robert G.

AU - Galloway, A.

AU - French, G.

AU - Street, M.

AU - Armstrong, J.

AU - Brown, E.

AU - Cleverley, J.

AU - Dilworth, P.

AU - Fry, Carole

AU - Gascoigne, A. D.

AU - Knox, Alan

AU - Nathwani, Dilip

AU - Spencer, Robert

AU - Wilcox, Mark

N1 - Funding Information: A. G. has received funds for speaking at a symposium organized on behalf of Wyeth Pharmaceuticals Ltd. R. S. has received personal remuneration for speaking at an educational meeting organized by Wyeth. R. G. M. has received speaker honoraria from AstraZeneca and Wyeth. D. N. presently is a member of a number of UK and European Pharmaceutical Advisory boards (tigecycline, Wyeth; ceftobiprole, Janssen-Cilag; daptomycin, Novartis; linezolid, Pfizer; and OPT-80, Optimer). He has received honoraria to speak at meetings organized by Pfizer, Wyeth and Novartis. M. W. has received honoraria for consultancy work, financial support to attend meetings and research funding from AstraZeneca, Bayer, Genzyme, Nabriva, Pfizer, Vicuron and Wyeth. A. D. G. and M. S. have received funds for speaking at symposia organized on behalf of Wyeth and E. B. has received fees for speaking at a symposium sponsored by Novartis and for being a member of advisory panels for Chiron, Novartis and Janssen-Cilag. He has also received sponsorship from Chiron to attend a conference. J. A., A. K., G. F., P. D., J. C. and C. F. have none to declare. Funding Information: We would like to acknowledge Corvus Communications Ltd and particularly Alison Crowe and Alistair Knight from within that company. Corvus Communications Ltd acted as the secretariat throughout this project and their support was from an unrestricted educational grant from Wyeth Pharmaceuticals Ltd, to whom we are also grateful for such funding.

PY - 2008/7

Y1 - 2008/7

N2 - These evidence-based guidelines have been produced after a systematic literature review of a range of issues involving prevention, diagnosis and treatment of hospital-acquired pneumonia (HAP). Prevention is structured into sections addressing general issues, equipment, patient procedures and the environment, whereas in treatment, the structure addresses the use of antimicrobials in prevention and treatment, adjunctive therapies and the application of clinical protocols. The sections dealing with diagnosis are presented against the clinical, radiological and microbiological diagnosis of HAP. Recommendations are also made upon the role of invasive sampling and quantitative microbiology of respiratory secretions in directing antibiotic therapy in HAP/ventilator-associated pneumonia.

AB - These evidence-based guidelines have been produced after a systematic literature review of a range of issues involving prevention, diagnosis and treatment of hospital-acquired pneumonia (HAP). Prevention is structured into sections addressing general issues, equipment, patient procedures and the environment, whereas in treatment, the structure addresses the use of antimicrobials in prevention and treatment, adjunctive therapies and the application of clinical protocols. The sections dealing with diagnosis are presented against the clinical, radiological and microbiological diagnosis of HAP. Recommendations are also made upon the role of invasive sampling and quantitative microbiology of respiratory secretions in directing antibiotic therapy in HAP/ventilator-associated pneumonia.

KW - Antimicrobial treatment

KW - Diagnosis

KW - Evidence-based guidelines

KW - Healthcare-associated pneumonia

KW - Hospital-acquired pneumonia

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=45749100460&partnerID=8YFLogxK

U2 - 10.1093/jac/dkn162

DO - 10.1093/jac/dkn162

M3 - Review article

C2 - 18445577

AN - SCOPUS:45749100460

SN - 0305-7453

VL - 62

SP - 5

EP - 34

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 1

ER -

Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this